Preparation and Characterization of MKT-077 Nanoparticles for Treatment of Alzheimer’s Disease and Other Tauopathies

Author(s): Umesh K. Jinwal, Aditya Grover, Malathi Narayan, Anjali Hirani, Vijaykumar Sutariya

Journal Name: Pharmaceutical Nanotechnology

Volume 2 , Issue 4 , 2014

Become EABM
Become Reviewer

Abstract:

Alzheimer’s disease is one of the most common causes of dementia and death in elderly populations. However, therapeutic intervention in Alzheimer’s disease is limited by the blood-brain barrier, which not only protects the brain by limiting the permeation of potential toxins into neural tissue but also by blocking certain drugs aimed at neurological disorders. MKT-077 is one such drug, which has shown promise in reducing Alzheimer’s disease- related pathology in cellular models but has limited brain permeation due to blockage by the blood-brain barrier. Herein, we describe the formulation and characterization of brain-targeted PEG-PLGA nanoparticles coated in 2% w/v glutathione to get higher blood-brain barrier permeation. Average nanoparticle size was found to be 230nm, suitable for intravenous administration and brain permeation. The nanoparticles showed steady, sustained release of MKT-077 in in vitro settings. Transwell in vitro blood-brain barrier model permeation studies showed the permeation of nanoparticles across the Transwell model to be greater than drug solution over 48 hours. The proposed model shows promise as a potential therapy against Alzheimer’s disease and other tauopathies.

Keywords: Alzheimer’s disease, blood-brain barrier, glutathione, MKT-077, nanoparticle, tau protein.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 2
ISSUE: 4
Year: 2014
Page: [217 - 226]
Pages: 10
DOI: 10.2174/2211738503666150328001726
Price: $65

Article Metrics

PDF: 16